RESUMEN
OBJETIVOS: Emitir recomendaciones sobre aspectos prácticos de la monitorización de los niveles de fármacos biológicos que puedan ser de utilidad para reumatólogos. MÉTODOS: Se realizó una revisión sistemática de la literatura de estudios en los que se determinaron niveles de fármaco y de anticuerpos antifármaco en pacientes con artritis reumatoide o espondiloartritis para estudiar si podían predecir diferentes desenlaces. Con los resultados de la revisión un grupo de expertos discutió bajo qué circunstancias podría ser útil la solicitud de niveles de fármacos biológicos y sus anticuerpos, lo que se concretó en una serie de preguntas clínicas que fueron respondidas con la evidencia científica disponible y creándose algoritmos para facilitar la toma de decisiones. RESULTADOS: Se establece que la determinación de los niveles de fármaco puede ser especialmente útil en 2 situaciones clínicas, cuando hay fallo al tratamiento (primario o secundario) y en remisión mantenida. Se revisa también qué técnica de laboratorio y momento para tomar la muestra son los más adecuados para la medición, y se establecen recomendaciones sobre la interpretación de los niveles de fármaco y sobre factores a tener en cuenta (por ejemplo, índice de masa corporal y fármacos modificadores de la enfermedad). CONCLUSIONES: Se han elaborado algoritmos y establecido posibles pautas y directrices para solicitar niveles de fármaco y de anticuerpos antifármaco en pacientes con artritis reumatoide y espondiloartritis, basados en la evidencia, que pueden ayudar a la toma de decisiones clínicas
OBJECTIVES: Issue recommendations on practical aspects of the monitoring of levels of biological drugs that may be useful for rheumatologists. METHODS: We conducted a systematic review of studies in which drug and anti-drug antibody levels were determined in patients with rheumatoid arthritis (RA) or spondyloarthritis (SpA) to study whether they could predict different outcomes. In light of the results of the review, a group of experts discussed under what circumstances testing biological drug levels and their antibodies could be useful. The discussion resulted in a series of clinical questions that were answered with the scientific evidence collected, and in algorithms that facilitate decision making. RESULTS: It was established that the determination of drug levels can be especially useful in two clinical situations, on treatment failure (primary or secondary) and on sustained remission. It is also reviewed which laboratory technique and timing for sample drawing are the most suitable for the measurement. Recommendations are issued on the interpretation of drug levels and on factors to be taken into account (for example, body mass index and disease modifying drugs). CONCLUSIONS: Evidence-based algorithms and guidelines have been established to test drug levels and anti-drug antibodies in patients with RA and SpA, which can help clinical decision making
Asunto(s)
Humanos , Terapia Biológica/métodos , Factores Biológicos/análisis , Monitoreo de Drogas/métodos , Antirreumáticos/análisis , Anticuerpos Monoclonales Humanizados/análisis , Enfermedades Reumáticas/tratamiento farmacológico , Administración del Tratamiento Farmacológico/organización & administración , Productos Biológicos/análisisRESUMEN
Resumen La Artritis Idiopática Juvenil es la enfermedad reumática más frecuente en niños. Es una enfermedad crónica, degenerativa y de etiología desconocida; que puede dejar múltiples secuelas en la población pediátrica. Consta de siete afecciones definidas por la International League of Associations for Rheumatology del 2001: Artritis Sistémica, Oligoartritis, Artritis con Factor Reumatoide positivo o Factor Reumatoide negativo, Artritis relacionada a entesitis, Artritis psoriasica y Artritis indiferenciada; distintas tanto en el aspecto clínico, patogénico como evolutivo. Esta enfermedad se caracteriza por una alteración de la regulación del sistema inmunitario innato con una falta de linfocitos T autorreactivos y autoanticuerpos. La inflamación continua estimula el cierre rápido y prematuro del cartílago de crecimiento provocando un acortamiento óseo. Para llegar a su diagnóstico no se requiere más que una buena historia clínica y examen físico, ya que no hay laboratorios o gabinete lo bastante sensible que nos puedan ayudar. Fármacos como el metrotexate y los inhibidores del factor de necrosis tumoral han venido a modificar la evolución de la enfermedad y mejorar la calidad de vida de estos pacientes.
Abstract Juvenile idiopathic arthritis is the most common rheumatic disease in children. It is a chronic and degenerative disease, with an unknown etiology; that can leave multiple sequels in the pediatric population. There are seven conditions defined by 2001 International League of Associations for Rheumatology: Systemic Arthritis, Oligoarthritis, Arthritis with positive rheumatoid factor or negative rheumatoid factor, enthesitis-related arthritis and undifferentiated arthritis; distinct in clinical, pathogenetic and evolutionary aspects. This disease is characterized by an alteration on the regulation of the innate immune system with a lack of autoreactive lymphocytes T and autoantibodies. Continuous inflammation stimulates the rapid and premature closure of the growth cartilage causing bone shortening. To arrive at the diagnosis, it is only necessary to have a good medical history and physical exam, since there are no laboratory test sensitive enough to help us. Drugs such as methotrexate and tumor necrosis factor inhibitors have come to modify the evolution of the disease and improve the quality of life of these patients.
Asunto(s)
Humanos , Preescolar , Niño , Adolescente , Artritis Juvenil/diagnóstico , Artritis Juvenil/tratamiento farmacológico , Líquido Sinovial/efectos de los fármacos , Antiinflamatorios no Esteroideos/uso terapéutico , Antirreumáticos/análisis , Factores de Necrosis Tumoral/uso terapéuticoRESUMEN
Rheumatoid arthritis (RA) is a chronic inflammatory disorder that causes pain, systemic complications and premature mortality. Depression has also been identified as a problem for persons with RA. This association remaining significant even after the degree of disease activity is controlled. In the present study, the efficacy of combination therapeutic effect of antidepressant (amitriptyline) with Disease Modifying Anti rheumatoid drug (leflunomide) was determined in rheumatoid arthritis pain associated depression in Freund's complete adjuvant (FCA) induced arthritic rats. Drug treatment was started 9 days after induction of FCA induced arthritis in rats. The antiarthritic activity was assessed by measuring paw volume, weight-bearing, hematological, biochemical, serological parameters, Radiographic analysis and Histopathology of tibiotarsal joints. The antidepressant activity was assessed by Forced swimming test, Rota-rod test and confirmed by estimation of brain neuro transmitters (serotonin and norepinephrine) level. Results of this study revealed that leflunomide and amitriptyline combination showed more significant (p<0.001) antiarthritic and antidepressant action and leflunomide alone treatment showed significant (p<0.001) antiarthritic activity only as compared to arthritic control. The leflunomide and low dose amitriptyline combination found to be more effective in pain associated depression in rheumatoid arthritic rats
Asunto(s)
Animales , Masculino , Ratas , Artritis , Depresión/inducido químicamente , Antidepresivos/análisis , Artritis Reumatoide/clasificación , Preparaciones Farmacéuticas/administración & dosificación , Antirreumáticos/análisisRESUMEN
RATIONALE: Herbal dietary supplements (HDSs) adulterated with undeclared synthetic drugs can lead to serious health problems METHODS: A fast-switching positive/negative high-voltage (+/- HV) was developed to apply on electrospray ionization mass spectrometry (ESI-MS) with porous tips for rapid screening of five antirheumatic drugs in antirheumatic HDSs. The fast-switching (switch-time: 100 ms) negative and positive ions were alternately generated to perform full-MS and tandem-MS analysis, providing an effective method for rapid detection of analytes in whichever mode of detection was most suitable (negative or positive ion mode). The use of different tips and solvents was also optimized in this work. RESULTS: The limits of detection of the five antirheumatic drugs were found to be less than 0.1 ng/g (S/N > 3). The reproducibility of the five drugs was measured to be 10.0-23.3% (n = 5). A single sample analysis could be completed within 1 min. Rapid screening of a total of 28 real HDS samples collected from the market was examined by the fast-switching HV substrate-tip ESI-MS method, and the screening result was further validated by conventional liquid chromatography/mass spectrometry. CONCLUSIONS: Overall, our results demonstrated that fast-switching HV substrate-tip ESI-MS is a rapid, reliable, and effective method for simultaneous screening of various analytes in complex samples.
Asunto(s)
Antirreumáticos/análisis , Contaminación de Medicamentos , Medicamentos Herbarios Chinos/análisis , Espectrometría de Masa por Ionización de Electrospray/métodos , Suplementos Dietéticos/análisis , Contaminación de Medicamentos/estadística & datos numéricos , Sensibilidad y EspecificidadRESUMEN
Rheumatoid arthritis (RA) is a common chronic disease with inflammatory and immunological background where treatments can only improve the symptoms and slow down the progress of the disease. Although there are several drugs with different therapeutic targets available in the market for the treatment of RA, conventional synthetic disease-modifying antirheumatic drugs (DMARDs) are the most effective option to date. Methotrexate, azathioprine, hydroxychloroquine, sulfasalazine, leflunomide, minocycline are commonly prescribed DMARDs by rheumatologists but they have the limitations of severe toxicity for which therapeutic drug monitoring is necessary. Many chromatographic methods are available for analysis of these drugs including their metabolites. However, they have not been critically reviewed for pre-chromatographic sample preparation, chromatographic separation and sensitive detection. This review article can be handy for quantitation of DMARDs in diverse biological matrices as it provides comprehensive information on the reported liquid chromatographic methods for last three decades covering all the aspects required for preclinical and clinical studies.
Asunto(s)
Antirreumáticos/análisis , Cromatografía Liquida/métodos , Antirreumáticos/uso terapéutico , Artritis Reumatoide/tratamiento farmacológico , HumanosRESUMEN
Rheumatoid arthritis (RA) is a chronic disease with systemic inflammation resulting in destruction of multiple articular cartilages and bones. Activated macrophage plays a pivotal role during the disease course and has been one of main targets to inhibit inflammatory reaction of RA by using biological disease-modifying anti-rheumatic drugs (bDMARDs). 18F-FEDAC is one of PET imaging agents targeting TSPO, which is overexpressed in activated macrophages. The aim of this study was to evaluate the roles of 18F-FEDAC PET as an in vivo imaging of activated macrophages on etanercept (ETN), a TNF-antagonist as one of bDMARDs in collagen induced arthritis mice. In RAW 264.7â¯cells, the expressions of TSPO as well as iNOS and infiltrated nucleus of NF-κB were induced by activation with lipopolysaccharide and interferon-gamma. TSPO expression was slightly attenuated by ETN treatment, not by methotrexate (MTX) as a cytotoxic agent. However, cell uptake of 18F-FEDAC did not show significant changes according to both of the treatments. Similarly in CIA mice, 18F-FEDAC uptake in inflamed paws on PET imaging did not show significant changes during both of the treatments, contrary to the uptake decrease of 18F-FDG, a glucose analog to reflect metabolic or active inflammatory activity. Interestingly, when we divided joints according to the degree of 18F-FEDAC uptake before ETN treatment, the joints of high 18F-FEDAC uptake showed better response to ETN than the joints with low 18F-FEDAC uptakes. In case of 18F-FDG, there was no such kinds of patterns. We can speculate that 18F-FEDAC PET imaging may identify activated macrophage-induced arthritis because that 18F-FEDAC can reflect activated macrophages, which is the therapeutic target of ETN by TNF antagonistic effect. Thus, in vivo imaging using 18F-FEDAC may be used as a predictor of therapeutic effects among those kinds of bDMARDs having anti-inflammatory actions to inhibit activated macrophage.
Asunto(s)
Acetamidas/uso terapéutico , Antirreumáticos/uso terapéutico , Macrófagos/metabolismo , Tomografía de Emisión de Positrones/métodos , Purinas/uso terapéutico , Acetamidas/metabolismo , Animales , Antiinflamatorios/farmacología , Antirreumáticos/análisis , Artritis Experimental/diagnóstico por imagen , Artritis Experimental/tratamiento farmacológico , Proteínas Portadoras/análisis , Proteínas Portadoras/metabolismo , Diagnóstico por Imagen/métodos , Monitoreo de Drogas/métodos , Etanercept/farmacología , Fluorodesoxiglucosa F18 , Humanos , Ligandos , Macrófagos/química , Ratones , Purinas/metabolismo , Células RAW 264.7 , Radiofármacos , Receptores de GABA-A/análisis , Receptores de GABA-A/metabolismoRESUMEN
For the last 30 years, pregnancy exposure studies, with varying methodologies, have been the mainstay of post-marketing surveillance for new drugs likely to be used by women of reproductive age. While they provide valuable data to inform use during pregnancy, they have limitations that render them necessary but not sufficient in supplying timely information to patients and prescribers. The Organization of Teratology Information Specialists MotherToBaby Pregnancy Studies' collaborative research group operates to help fill this gap. This paper provides an overview of the research that has been and is currently being conducted, as well as best practices determined over the past two decades. The Organization of Teratology Information Specialists MotherToBaby studies can provide earlier signaling with regard to concerns following possible teratogenic exposures, which when examined in conjunction with larger database studies and case-control designs, can move us closer to developing a fuller picture of drug safety for women of reproductive age.
Asunto(s)
Antirreumáticos/análisis , Exposición Materna , Complicaciones del Embarazo/tratamiento farmacológico , Enfermedades Reumáticas/tratamiento farmacológico , Teratógenos/análisis , Teratología/métodos , Antirreumáticos/efectos adversos , Estudios de Casos y Controles , Femenino , Humanos , Exposición Materna/efectos adversos , Embarazo , Estudios ProspectivosRESUMEN
In this study, we have developed a facile method for preparation of highly fluorescent Au nanoclusters (AuNCs) using 11-mercaptoundecanoic acid (MUA) as both the reducing and stabilizing agent. The as-prepared MUA functionalized AuNCs (MUA-AuNCs) have good water solubility, excellent photostability, and strong fluorescence emission at 610 nm with a quantum yield of 7.28% in water. The fluorescence of MUA-AuNCs was first quenched by copper ions through electron transfer, subsequently caused obvious restoration by competitive effect after adding penicillamine, making it a potential fluorescent sensor for penicillamine with a detection limit of 0.08 µM. Furthermore, the newly designed fluorescence "on-off-on" assay was explored for the measurement of penicillamine in complex real water and urine samples with satisfactory results.
Asunto(s)
Antirreumáticos/análisis , Ácidos Grasos/química , Colorantes Fluorescentes/química , Oro/química , Nanopartículas del Metal/química , Penicilamina/análisis , Compuestos de Sulfhidrilo/química , Contaminantes Químicos del Agua/análisis , Antídotos/análisis , Antídotos/farmacocinética , Antirreumáticos/orina , Cobre/química , Excipientes/química , Humanos , Lagos/análisis , Límite de Detección , Nanopartículas del Metal/ultraestructura , Penicilamina/orina , Sustancias Reductoras/química , Espectrometría de Fluorescencia/métodos , Contaminantes Químicos del Agua/orinaRESUMEN
BACKGROUND: Women with chronic inflammatory diseases face uncertainty regarding the safety of biologics during breast feeding. CRADLE was the first industry-sponsored study to evaluate certolizumab pegol (CZP) concentrations in human breast milk and estimate average daily infant dose (ADID) of maternal CZP. METHODS: CRADLE (NCT02154425) was a pharmacokinetic study of lactating mothers receiving CZP. After ≥3 CZP doses, breast milk samples were collected across one dosing period (14 days for 200 mg every 2 weeks [Q2W]; 28 days for 400 mg every 4 weeks [Q4W]). Optimal analytical methods were developed to determine CZP and polyethylene glycol (PEG) levels in breast milk. ADID and relative infant dose (RID) were estimated. Safety events in mothers and infants were assessed. RESULTS: 19 CZP-treated mothers were screened; 17 entered the sampling period: 16 on 200 mg Q2W, 1 on 400 mg Q4W. 77/137 (56%) breast milk samples had no measurable CZP. For 4/17 mothers, all samples were below the lower limit of quantification (LLOQ). Estimated ADID was 0-0.0104 mg/kg/day; median RID: 0.15%. PEG was undetectable in 134/137 samples (results could not be determined in three samples). Infants of CZP-exposed mothers had a safety profile consistent with that of unexposed similar-age infants. CONCLUSION: When quantifiable, CZP concentrations were <3× LLOQ (<1% plasma concentration observed with therapeutic dose), indicating no/minimal CZP transfer from plasma to breast milk. RID was 0.15% of maternal dose; <10% is considered unlikely to be of clinical concern. No PEG transfer was observed. CZP absorption by infants via breast milk is unlikely due to its low oral bioavailability and Fc--free molecular structure. These findings are reassuring and support continuation of CZP treatment during breast feeding. TRIAL REGISTRATION NUMBER: NCT02154425; Results.
Asunto(s)
Antirreumáticos/farmacocinética , Certolizumab Pegol/farmacocinética , Leche Humana/efectos de los fármacos , Enfermedades Reumáticas/tratamiento farmacológico , Adulto , Antirreumáticos/análisis , Certolizumab Pegol/análisis , Femenino , Humanos , Lactante , Recién Nacido , Leche Humana/química , Polietilenglicoles/análisis , Vigilancia de Productos Comercializados , Estudios ProspectivosRESUMEN
ABSTRACT Natural compounds are a gold mine for treating rheumatoid arthritis (RA). The etiology of this disease is linked to inflammation, where cytokines play an important role. Strategies have been drafted for targeting cytokines as a therapeutic option in patients with RA. Inhibiting cytokines with natural compounds has become a major focus for the development of drugs to treat RA. Here, a structure-based drug design approach was employed to identify novel leads to target the interleukin 6 receptor (IL-6R). A total of 48,531 compounds of natural origin were screened. Two of these compounds were shortlisted for molecular docking simulation and tested for inhibiting gp130 dimerization in human macrophages. The results show that Lead5 (CID5329098) significantly inhibited the release of gp130 in a dose-dependent manner, similar to the inhibitory effect of LMT-28 (p<0.005). This study provides an atomic scale outcome of a single natural compound that can be developed into a RA drug
Asunto(s)
Artritis Reumatoide/tratamiento farmacológico , Citocinas , Receptores de Interleucina , Antirreumáticos/análisisRESUMEN
Methotrexate (MTX), a common pharmaceutical drug in cancer therapy and treatment of rheumatic diseases, is known to cause severe adverse side effects at high dose. As the side effect may be life threatening, there is an urgent need for a continuous, bed-side monitoring of the nominal MTX serum level in a patient while the chemical is being administered. This article describes a detection of MTX using a flow system that consists two modified gold electrodes. Interaction of MTX with the antibodies fixed on the electrode surface is detected by electrochemical impedance spectroscopy and evaluated using singular value decomposition (SVD). The key finding of this work is that the change in the electrode capacitance is found to be quantitative with respect to the concentration of MTX. Moreover a calibration curve constructed using the principal component regression method has a linear range of six orders of magnitude and a detection limit of 1.65 × 10(-10) M.
Asunto(s)
Espectroscopía Dieléctrica/métodos , Metotrexato/análisis , Antimetabolitos Antineoplásicos/análisis , Antirreumáticos/análisis , Análisis MultivarianteRESUMEN
OBJECTIVES: To evaluate the relevance of anti-adalimumab (anti-ADA) antibodies (Abs) and their relationship with clinical/laboratory features in rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA). METHODS: Fifty-eight patients affected with RA, AS and PsA were prospectively enrolled. Clinical/laboratory characteristics, disease activity, anti-ADA, anti-nuclear (ANA), anti-double strand (ds)DNA, anti-extractable nuclear antigens (anti-ENA) and anti-phospholipid Abs (aPL) were evaluated at baseline, 4, 12 and 24 weeks of adalimumab treatment. RESULTS: Anti-ADA Abs were observed in 11/58 (19%) patients; they were detected within the 4th week of therapy in 90.9% of the positive subjects. Anti-ADA positivity was associated with significantly lower mean adalimumab serum levels (P<0.05). Treatment failure was observed in 20/58 (34.5%) patients and was significantly associated with anti-ADA Abs (P<0.05). Mean adalimumab serum levels were significantly lower in patients with treatment failure than in the responders one, both in the whole cohort (P<0.01) and in the group of anti-ADA positive patients (P<0.01). Adverse events happened more often in anti-ADA positive then in anti-ADA negative patients (27.3% vs 14.9%). CONCLUSIONS: Anti-ADA abs could be considered an early marker associated to a poor clinical response to adalimumab treatment. Routine ANA/anti-ENA/aPL monitoring did not reveal as useful tools to predict the development of anti-ADA abs.
Asunto(s)
Adalimumab/inmunología , Anticuerpos Monoclonales Humanizados/inmunología , Antirreumáticos/inmunología , Artritis Psoriásica/inmunología , Artritis Reumatoide/inmunología , Espondilitis Anquilosante/inmunología , Adalimumab/análisis , Adulto , Anticuerpos Monoclonales Humanizados/análisis , Antirreumáticos/análisis , Artritis Psoriásica/tratamiento farmacológico , Artritis Reumatoide/tratamiento farmacológico , Diagnóstico Precoz , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Espondilitis Anquilosante/tratamiento farmacológicoRESUMEN
OBJECTIVE: Due to reduction of immune-suppressive drugs, patients with rheumatic diseases can experience an increase in disease activity during pregnancy. In such cases, TNF-inhibitors may be prescribed. However, monoclonal antibodies with the Fc moiety are actively transported across the placenta, resulting in therapeutic drug levels in the newborn. As certolizumab (CZP) lacks the Fc moiety, it may bear a lower risk for the child. METHOD: We report a case series of thirteen patients (5 with rheumatoid arthritis and 8 with spondyloarthritis) treated with CZP during late pregnancy to control disease activity. RESULT: CZP measured in cord blood of eleven infants ranged between undetectable levels and 1µg/mL whereas the median CZP level of maternal plasma was 32.97µg/mL. Three women developed an infection during the third trimester, of whom one had a severe infection and one had an infection that resulted in a pre-term delivery. During the postpartum period, 6 patients remained on CZP while breastfeeding. CZP levels in the breast milk of two breastfeeding patients were undetectable. CONCLUSION: The lack of the active transplacental transfer of CZP gives the possibility to treat inflammatory arthritis during late gestation without potential harm to the newborn. However, in pregnant women treated with TNF-inhibitors and prednisone, attention should be given to the increased susceptibility to infections, which might cause prematurity. CZP treatment can be continued while breastfeeding.
Asunto(s)
Antirreumáticos/efectos adversos , Artritis Reumatoide/tratamiento farmacológico , Certolizumab Pegol/efectos adversos , Sangre Fetal/química , Complicaciones Infecciosas del Embarazo/inducido químicamente , Espondiloartritis/tratamiento farmacológico , Antirreumáticos/administración & dosificación , Antirreumáticos/análisis , Certolizumab Pegol/administración & dosificación , Certolizumab Pegol/análisis , Femenino , Humanos , Recién Nacido , Embarazo , Nacimiento Prematuro/inducido químicamente , Medición de Riesgo , Factores de RiesgoRESUMEN
Dianbaizhu, a folk medicine from Gaultheria leucocarpa BLUME var. yunnanensis (FRANCH.) T. Z. HSU & R. C. FANG (Ericaceae) used as an antirheumatic, has multiple plant origins and officinal parts. A rapid high-performance liquid chromatography with diode array detector (HPLC-DAD) method was established for the simultaneous determination of the characteristic ingredient methyl benzoate-2-O-ß-D-glucopyranosyl(1 â 2) [O-ß-D-xylopyranosyl(1 â 6)]-O-ß-D-glucopyranoside and seven bioactive constituents in eight Gaultheria species. This chromatographic method is precise, accurate, and stable. Kruskal-Wallis analysis, hierarchical cluster analysis, and factor analysis were used to analyze the content of reference compounds in different Gaultheria species and officinal parts. The analyses showed significant differences (p<0.05) in Gaultheria species but few differences (p>0.05) in their medicinal parts. G. leucocarpa var. yunnanensis appeared to the best among the Gaultheria species tested for the treatment of rheumatic diseases. Taken together, the results show that this simultaneous quantiï¬cation of multiple active constituents using HPLC-DAD combined with chemometrics can be reliably applied to evaluate the quality of Dianbaizhu.
Asunto(s)
Antirreumáticos/aislamiento & purificación , Benzoatos/aislamiento & purificación , Gaultheria/química , Glucósidos/aislamiento & purificación , Medicina Tradicional , Extractos Vegetales/química , Antirreumáticos/análisis , Benzoatos/análisis , Cromatografía Líquida de Alta Presión/métodos , Análisis por Conglomerados , Glucósidos/análisisRESUMEN
Los medicamentos de origen biotecnológico pueden ser anticuerpos monoclonales o moléculas pequeñas diseñadas para actuar sobre blancos terapéuticos definidos. Se hizo una búsqueda de publicaciones en PubMed y ScienceDirect, FDA. Se obtuvo la información sobre mecanismos de acción, blancos terapéuticos, principales aspectos farmacocinéticos, reacciones adversas más frecuentes e importantes y los usos aprobados y en investigación. Se describen los anticuerpos monoclonales según los grupos farmacológicos a los que pertenecen, inhibidores de la tirosina cinasa; inhibidores del proteasoma y bloqueadores de la coestimulación de células T. Son significativos los avances en el tratamiento del cáncer y enfermedades reumáticas, pero van acompañados de elevados costos y toxicidad no despreciable
Biotechnology drugs may be monoclonal antibodies or small molecules designed to act on defined therapeutic targets. Was made a search in PubMed, ScienceDirect and FDA. Information on mechanisms of action, therapeutic targets, main pharmacokinetic aspects, more frequent and significant adverse reactions and approved uses and research was obtained. It describes monoclonal antibodies as the drug groups to which they belong, tyrosine kinase inhibitors; proteasome inhibitors and blockers of T cell costimulation. Are significant advances in the treatment of many diseases, especially cancer and rheumatic diseases, but are accompanied by high costs and frequent toxicity
Asunto(s)
Biotecnología/tendencias , Anticuerpos Monoclonales/análisis , Inhibidores de Proteasoma/análisis , Proteínas Tirosina Quinasas/antagonistas & inhibidores , Receptores Coestimuladores e Inhibidores de Linfocitos T/análisis , Antineoplásicos/análisis , Antiinflamatorios/análisis , Antirreumáticos/análisisRESUMEN
Chronotherapeutic drug delivery offers a new approach in the pharmacologic interventions design for the effective treatment in the diseases which follows circadian rhythm. In the present study chronotherapeutic tablets of indometacin was designed to match the timing of rheumatoid arthritis treatment with the intrinsic illness timing. The developed chronotherapeutic delivery system consists of a core tablet containing the active ingredient along with osmogents and other excipients, which was coated with a swellable polymer, hydroxyl propyl methyl cellulose by compression coating technique. The time controlled release was achieved by coating the entire system with a combination of pH-independent polymer, Eudragit RS 100 and Eudragit RL 100 (1:1). The optimization technique using Box-Behnken design was employed for the selection of the ideal formula. The optimization procedure was validated, and the observed value of the ideal batch was found to be similar with the predicted values within 5% of predicted error. The formulation when administered at bed time starts releasing the drug after a lag time of 4 h and provides sufficient plasma concentration after 6 h of normal sleep. Thus, the tablets can be successfully used for the chronotherapeutic drug delivery of indometacin in the treatment of rheumatoid arthritis.
Asunto(s)
Antiinflamatorios no Esteroideos/química , Antirreumáticos/química , Excipientes/química , Indometacina/química , Modelos Químicos , Resinas Acrílicas/química , Antiinflamatorios no Esteroideos/análisis , Antirreumáticos/análisis , Química Farmacéutica/métodos , Preparaciones de Acción Retardada , Cronoterapia de Medicamentos , Estabilidad de Medicamentos , Humanos , Concentración de Iones de Hidrógeno , Derivados de la Hipromelosa , Indometacina/análisis , Cinética , Metilcelulosa/análogos & derivados , Metilcelulosa/química , Modelos Biológicos , Solubilidad , Estadística como Asunto , Propiedades de Superficie , Comprimidos , Agua/análisisRESUMEN
The folate antagonist methotrexate (MTX) is the anchor drug in the treatment of rheumatoid arthritis. The therapeutic effects of MTX are attributed to the intracellular levels of MTX, present in the cell as polyglutamates (MTXPGn). We developed a new liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS)-based assay to separately quantitate MTXPGn in red blood cells using stable-isotope-labelled internal standards. Samples were analyzed by LC-ESI-MS/MS using a Waters Acquity UPLC BEH C18 column with a 5-100% organic gradient of 10 mM ammonium bicarbonate (pH 10) and methanol. The analysis consisted of simple sample preparation and a 6-min run time. Detection was done using a Waters Acquity UPLC coupled to a Waters Quattro Premier XE with electrospray ionization operating in the positive ionization mode. Assay validation was performed following recent Food and Drug Administration guidelines. The method was linear from 1-1,000 nM for all MTXPGn (R(2) > 0.99). The coefficient of variation ranged from 1-4% for intraday precision and 6-15% for interday precision. Samples were stable for at least 1 month at -80 °C. Recovery ranged from 98-100%, and the relative matrix-effect varied from 95-99%. The lower limit of quantitation was 1 nM for each MTXPGn. Fifty patient samples from the tREACH study were analyzed. The MTXPGn concentration and distribution of these samples were comparable with values reported in literature. The developed LC-ESI-MS/MS method for the quantitative measurement of MTXPGn in red blood cells is both sensitive and precise within the clinically relevant range. The method can be easily applied in clinical laboratories due to the combination of simple pre-treatment with robust LC-ESI-MS/MS.
Asunto(s)
Antirreumáticos/sangre , Artritis Reumatoide/tratamiento farmacológico , Monitoreo de Drogas/métodos , Eritrocitos/química , Metotrexato/sangre , Ácido Poliglutámico/sangre , Espectrometría de Masa por Ionización de Electrospray/métodos , Antirreumáticos/análisis , Artritis Reumatoide/sangre , Cromatografía Líquida de Alta Presión/métodos , Humanos , Límite de Detección , Metotrexato/análisis , Ácido Poliglutámico/análisis , Sensibilidad y Especificidad , Espectrometría de Masas en Tándem/métodosRESUMEN
Total reflection X-ray spectrometry is an instrumental technique based on X-ray fluorescence, which offers detection limits low enough to quantify trace element concentrations with negligible interference from matrix components. The technique is well established in material sciences and now reaches out to extended applications in life sciences and pharmaceutical quality control. In our study we focused on possible applications for the quantification of gold and platinum containing active ingredients in trace concentrations (ppb range) in a matrix of biological origin (cell suspensions). General aspects of sample preparation as well as selected important method performance parameters (precision, recovery rates) were investigated. Overall, TXRF represents an useful option to quantify metals in ppb concentrations with acceptable precision and recovery.
Asunto(s)
Antineoplásicos/análisis , Antirreumáticos/análisis , Auranofina/análisis , Cisplatino/análisis , Espectrometría por Rayos X , Antineoplásicos/metabolismo , Antirreumáticos/metabolismo , Auranofina/metabolismo , Calibración , Extractos Celulares/química , Cisplatino/metabolismo , Células HT29 , Humanos , Límite de Detección , Proyectos Piloto , Estándares de Referencia , Reproducibilidad de los Resultados , Espectrometría por Rayos X/normasRESUMEN
Methotrexate is prescribed to low-dose, ranging from 7.5 mg to 15 mg and until 25 mg if necessary, pulse once a week, in inflammatory pathologies, in particular in rheumatoid arthritis and psoriasis. The therapeutic answer and the frequency of adverse reactions are very variable from a patient to the other one, consequences of a large interindividual variability of the pharmacokinetic parameters of methotrexate, in particular bioavailability, suggesting a genetic support. Numerous polymorphisms being involved (carriers of influx and efflux, enzymes of the metabolism and of the mechanism of action of methotrexate), their determination with the aim of an individualized prescription does not seem realistic at the moment. On the other hand, an exposure-effect relationship, not so much by considering the plasma concentrations of methotrexate, but those of its polyglutamate derivatives in red blood cells, was described. Their determination should be able to contribute to a faster adaptation of dosages, or to a well-argued change of molecule in case of non clinical response. Although other studies are necessary to specify which markers would be the most relevant, which would be the best moment for their determination and to refine the therapeutic range, this approach seems promising. But currently, the level of proof of the therapeutic drug monitoring of low dose methotrexate in inflammatory disease was classified "remaining to evaluate".
Asunto(s)
Antirreumáticos/uso terapéutico , Monitoreo de Drogas/métodos , Inmunosupresores/uso terapéutico , Inflamación/tratamiento farmacológico , Metotrexato/uso terapéutico , Antirreumáticos/efectos adversos , Antirreumáticos/análisis , Antirreumáticos/farmacocinética , Artritis Reumatoide/tratamiento farmacológico , Relación Dosis-Respuesta a Droga , Medicina Basada en la Evidencia , Humanos , Metotrexato/efectos adversos , Metotrexato/análisis , Metotrexato/farmacocinética , Psoriasis/tratamiento farmacológico , Insuficiencia Renal/metabolismoRESUMEN
Aerosol drugs dominate a significant share of pharmaceutical preparations on the market. A novel sensitive method utilizing nano extractive electrospray ionization mass spectrometry (nanoEESI-MS) has been developed for the rapid analysis of aerosol drug samples with quantitative information. Without any sample pretreatment, aerosol drugs were manually sprayed into the primary ion plume created by a nano electrospray emitter for direct ionization under ambient conditions. The analyte ions of interest were guided into an ion trap mass spectrometer for tandem mass analysis. The active ingredients of various aerosol drugs, such as econazole nitrate, beclomethasone dipropionate, binary mixture of methyl salicylate and diphenhydramine, terbutaline, and salbutamol, were rapidly detected using nanoEESI-MS. A single sample analysis could be completed within 1.2 s. Tandem mass spectrometry was used to confirm the identification of important compounds in each aerosol drug sample. Reasonable relative standard deviation (RSD = 6.39%, n = 13) and acceptable sensitivity (10 ppt, 100 muL) were found for the salbutamol aerosol sample, which suggests that nanoEESI-MS has the quantitative capacity for analyzing complex pharmaceutical samples. This method was further extended to study the thermal decomposition process of salbutamol, showing that the degradation kinetics of salbutamol can be conveniently tracked. Our data demonstrate that nanoEESI tandem mass spectrometry is a fast and sensitive technique for the analysis of aerosol drug preparations, showing promising applications in pharmacology studies and in situ analysis of aerosol drugs on the market.